eloralintide vs tirzepatide Triple Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Eloralintide Phase 2 Topline results

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)

At 10 mg/mL, a 2.5 mg dose equals 25 units and a 10 mg dose equals 100 units

This is not a decision to be taken lightly, as there are several important factors to consider when determining whether this is a suitable path for you based on your personal circumstances

This explains why Ozempic face photos and Ozempic face aging examples show sharper cheekbones and deeper folds

Over time, this allows the body to use stored fat for energy, leading to fat loss and improved body composition